Analyzing Spruce Biosciences (NASDAQ:SPRB) & ProMetic Life Sciences (OTCMKTS:PFSCF)

Spruce Biosciences (NASDAQ:SPRB) and ProMetic Life Sciences (OTCMKTS:PFSCF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Volatility & Risk

Spruce Biosciences has a beta of 3.62, indicating that its share price is 262% more volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500.

Valuation & Earnings

This table compares Spruce Biosciences and ProMetic Life Sciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91 million	14.61	-$38.97 million	($51.72)	-1.01
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A

Spruce Biosciences has higher earnings, but lower revenue than ProMetic Life Sciences.

Institutional and Insider Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 0.1% of ProMetic Life Sciences shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Spruce Biosciences and ProMetic Life Sciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	2	4	0	2.43
ProMetic Life Sciences	0	0	0	0	0.00

Spruce Biosciences presently has a consensus price target of $203.25, suggesting a potential upside of 288.18%. Given Spruce Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than ProMetic Life Sciences.

Profitability

This table compares Spruce Biosciences and ProMetic Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-203.99%	-127.96%
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%

Summary

Spruce Biosciences beats ProMetic Life Sciences on 10 of the 12 factors compared between the two stocks.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.